SCHEMBL25422658

SCHEMBL25422658

Cc1nc(-c2nnn(C)c2COC2CCCCO2)ccc1B(O)O

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SLCO1B1 Q9Y6L6 4/20 0.37
▸ ABCB11 O95342 3/20 0.37
▸ ABCC3 O15438 2/20 0.37
▸ ABCC4 O15439 2/20 0.37
▸ SLCO1B3 Q9NPD5 2/20 0.37
▸ LPAR1 Q92633 1/20 0.37
▸ TGFBR1 P36897 1/20 0.34
▸ TGFBR2 P37173 1/20 0.34
▸ KDM4C Q9H3R0 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ DRD2 P14416 1/20 0.31
▸ DRD4 P21917 1/20 0.31
▸ MEN1 O00255 1/20 0.30
▸ KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29411759 0.88 SLCO1B1 (0.38) SLCO1B1ABCB11ABCC3ABCC4SLCO1B3
SCHEMBL19715757 0.88 SLCO1B1 (0.38) SLCO1B1ABCB11ABCC3ABCC4SLCO1B3
SCHEMBL24982985 0.88 SLCO1B1 (0.39) SLCO1B1ABCB11ABCC3ABCC4SLCO1B3
SCHEMBL29068133 0.86 SLCO1B1 (0.37) SLCO1B1ABCB11ABCC3ABCC4SLCO1B3
SCHEMBL19715601 0.86 SLCO1B1 (0.36) SLCO1B1ABCB11ABCC3ABCC4SLCO1B3
SCHEMBL29068103 0.85 SLCO1B1 (0.36) SLCO1B1ABCB11ABCC3ABCC4SLCO1B3
SCHEMBL30452478 0.85 SLCO1B1 (0.36) SLCO1B1ABCB11ABCC3ABCC4SLCO1B3
SCHEMBL29068148 0.83 SLCO1B1 (0.39) SLCO1B1ABCB11ABCC3ABCC4SLCO1B3
SCHEMBL30453259 0.83 SLCO1B1 (0.39) SLCO1B1ABCB11ABCC3ABCC4SLCO1B3
SCHEMBL19715607 0.82 SLCO1B1 (0.39) SLCO1B1ABCB11ABCC3ABCC4SLCO1B3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066341-A1 CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2025-02-27 — — US disclosed
EP-4452965-A1 CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-10-30 — — EP disclosed
WO-2023118253-A1 CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2023-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066341-A1 CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS LPAR1, LPAR2, LPAR3 SLCO1B1 2746/4885ABCB11 1315/4885ABCC3 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback